The compounding pharmacy market is anticipated to experience a Compound Annual Growth Rate (CAGR) of 2.18% from 2022 to 2027, resulting in a forecasted increase of USD 1,682.04 million in market size.
This growth is influenced by various factors, including the rising demand for compounded medications driven by the popularity of Hormone Replacement Therapy (HRT), the increasing prevalence of hormonal imbalance issues, and the impact of government regulations and initiatives.
Market Segmentation: The report extensively covers market segmentation by product, including topical medications, oral medications, parenteral medications, and other medications. Therapeutic areas explored in the report include pain management, hormone replacement, dermal disorders, and other therapeutic areas. Geographical segmentation encompasses North America, Europe, Asia, and the Rest of the World (ROW). The analysis also delves into historic market data from 2017 to 2021.
Key Drivers: The growing popularity of HRT driving demand for compounded medications is a significant driver for market growth. Increased awareness of health issues and the need for personalized HRTs, addressing concerns such as mood swings, hot flashes, depression, and more, has led to a surge in demand for compounded medications, particularly in the hormonal replacement therapy segment.
Key Trends: A noteworthy trend is the rising popularity of personalized medicines, with compounding pharmacies playing a crucial role in early disease detection and accurate treatment. The adoption of microarray technology for genetic profiling and the awareness of genetic diseases are driving the development of compounding pharmacies focused on targeted drug development.
Key Challenges: One key challenge is the unsafe usage of compounded drugs, primarily due to improper compounding techniques leading to contamination and disregard for Good Manufacturing Practice (GMP) guidelines. Regulatory restrictions on certain compounded medications, as exemplified by the FDA’s list of prohibited drugs, pose a threat to the market’s growth.
Customer Landscape: The report includes an analysis of the market’s adoption lifecycle, covering innovators to laggards, and provides insights into key purchase criteria and drivers of price sensitivity to aid companies in refining their growth strategies.
Market Share and Major Companies: Vendors are adopting various strategies such as alliances, partnerships, mergers, acquisitions, and product/service launches. Key players include Fresenius SE and Co. KGaA, ACPHARM QUEENSLAND Pty Ltd., Advance Pharmacy, Athenex Inc., and others.
Largest-Growing Segments: The topical medications segment is projected to witness significant growth, attributed to the diverse dosages available and their effectiveness in treating skin diseases.
Key Regions: Asia is expected to contribute 37% to the global market growth, with North America offering significant opportunities due to the prevalence of chronic diseases, the presence of pharmaceutical companies, and the outsourcing of drug development and manufacturing.
Market Segmentation Overview: The report provides a detailed breakdown of market segmentation, covering product types (topical medications, oral medications, parenteral medications, other medications), therapeutic areas (pain management, hormone replacement, dermal disorders, other therapeutic areas), and geographical regions (North America, Europe, Asia, ROW).
Competitive Landscape: The report profiles 20 market vendors, including detailed analyses of their competitive strategies, market positioning, and information on key players such as ACPHARM QUEENSLAND Pty Ltd., Fresenius SE and Co. KGaA, and others.
Market Dynamics: The report analyzes the parent market, factors influencing growth, inducers, obstacles, fast and slow-growing segments, COVID-19 impact, recovery analysis, and future consumer dynamics.
Customization: The report offers customization options to address specific data requirements beyond the presented analysis. Stakeholders can reach out to analysts for personalized segments or additional information not covered in the report.